Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.King Pharmaceuticals has commenced a pivotal phase III clinical trial program evaluating its investigational drug Vanquix as a treatment for acute repetitive seizures associated with epilepsy.
Subscribe to our email newsletter
“Currently, there is no commercially available adjunctive injectable therapy, outside of a hospital setting, for the emergency treatment of acute repetitive epileptic seizures,” said Michael Jolly, executive vice president of R&D at King. “We believe Vanquix has the potential to effectively address this unmet medical need.”
At present, the only product commercially available for the management of patients with acute, repetitive seizures by a caregiver who is not a healthcare professional is a diazepam rectal gel. This product requires a patient to retain the gel in the rectum for absorption to occur and may be difficult to administer during a seizure. Vanquix is designed to provide a superior means of delivering diazepam to such patients.